Where will the (New) Drugs for Traumatic Brain Injury Treatment be Coming From?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Fluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the Bedside.International journal of molecular sciences · 2023
   Review
2. Big Data in traumatic brain injury; promise and challenges.Concussion (London, England) · 2017
   Review
3. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.Neuropharmacology · 2017
   Review
4. Of Timescales, Animal Models, and Human Disease: The 50th Anniversary of C. elegans as a Biological Model.Frontiers in neurology · 2013
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.